Across TCGA pan-cancer cohorts, SLC39A9 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SLC39A9’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC39A9 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC39A9 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.
LUAD, PDAC, and CCRCC are the cancer types where SLC39A9 tumor–normal differential expression is most reproducible.